Skip to main content
Equibles
NSPR logo

NSPR · InspireMD, Inc. · Webcasts, Transcripts & Audio

Track NSPR — free

Use NSPR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NSPR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.58 -0.04 (-6.83%) At close · Oct 5
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management has concluded that there is substantial doubt about our ability to continue as a going concern, and our condensed financial statements for the quarter ended June 30, 2026 includes an explanatory paragraph as to our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.”
View the 10-Q filed Aug 14, 2026
Market Cap
$32.54M
Shares
46.49M
Volume · Oct 5 136.22K Avg daily vol (3M) 73.23K

InspireMD, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for InspireMD, Inc. (NSPR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲47.5% $1.53M −$4.64M '22 Q2 22-08-11 ▲33.6% $1.43M −$4.53M '22 Q3 22-11-08 ▼25.7% $1.03M −$4.84M '22 Q4 23-03-30 ▲4.7% $1.24M −$4.26M '23 Q1 23-05-16 ▲7.7% $1.65M −$5.08M '23 Q2 23-08-08 ▲8.7% $1.56M −$5.18M '23 Q3 23-11-06 ▲71.6% $1.76M −$5.41M '23 Q4 24-03-06 ▲22% $1.51M −$7.03M '24 Q1 24-05-14 ▲5.5% $1.74M −$7.91M '24 Q2 24-08-06 ▲16.3% $1.81M −$7.89M '24 Q3 24-09-30 ▲10.7% $1.95M −$9.17M '24 Q4 25-03-12 ▲1.2% $1.53M −$11.17M '25 Q1 25-05-09 ▲2.2% $1.78M −$13.15M '25 Q2 25-08-05 ▲39.4% $2.52M −$12.71M '25 Q3 25-11-04 ▲122.2% $3.40M −$13.69M '26 Q1 26-05-04 LATEST ▼0.4% $1.77M −$14.32M '26 Q2 26-08-17
Earnings call
FY26 · Q2
2026-08-17
InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript
Positive tone U.S. regulatory catalysts and approvals International/OUS business growth Organization and cost structure alignment
Revenue
$1.77M
▼ 0.4% YoY
Diluted EPS
$-0.17
Gross margin
-43.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-04
InspireMD, Inc. (NSPR) Q1 2026 Earnings Call Transcript
Balanced tone Voluntary U.S. pause of Seaguard Prime 135 delivery system TCAR strategy with Seaguard Prime 80 International (OUS) revenue growth
Revenue
$3.40M
▲ 122.2% YoY
Diluted EPS
$-0.16
▼ 172.7% YoY
Gross margin
20.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q3
2025-11-04
InspireMD, Inc. (NSPR) Q3 2025 Earnings Call Transcript
Confident tone U.S. Launch of CGuard Prime International Business Clinical Trial Pipeline
Revenue
$2.52M
▲ 39.4% YoY
Diluted EPS
$-0.17
Gross margin
34.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript
Confident tone C-GUARDIANS II pivotal TCAR study FDA approval and U.S. commercial launch of CGuard Prime Stent-first carotid intervention market opportunity
Revenue
$1.78M
▲ 2.2% YoY
Diluted EPS
$-0.26
Gross margin
17.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-09
InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript
Confident tone CGuard Prime U.S. FDA Approval FDA Timeline and Regulatory Uncertainty Market Opportunity and Procedural Shift
Revenue
$1.53M
▲ 1.2% YoY
Diluted EPS
$0.22
Gross margin
19.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-12
InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript
Confident tone CGuard Prime US Launch TCAR Market Opportunity Clinical Pipeline and Studies
Revenue
$1.95M*
▲ 10.7% YoY
Gross margin
24.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-09-30
InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript
Confident tone U.S. CGuard Prime Approval & Launch TCAR Pipeline (SwitchGuard / CGuardians II) U.S. Launch Targeting Strategy
Revenue
$1.81M
▲ 16.3% YoY
Diluted EPS
$-0.16
Gross margin
22.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript
Confident tone C-GUARDIANS pivotal trial data and PMA submission SwitchGuard TCAR platform and pipeline CREST-2 clinical trial completion
Revenue
$1.74M
▲ 5.5% YoY
Diluted EPS
$-0.22
Gross margin
19.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
InspireMD, Inc. (NSPR) Q1 2024 Earnings Call Transcript
Confident tone SwitchGuard / TCAR Development C-Guardians Pivotal Trial and U.S. PMA CGuard Revenue Growth
Revenue
$1.51M
▲ 22% YoY
Diluted EPS
$-0.21
Gross margin
19.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
InspireMD, Inc. (NSPR) Q4 2023 Earnings Call Transcript
Confident tone CGuard carotid stent platform and commercial growth C-Guardians U.S. pivotal trial and PMA timeline SwitchGuard / C-Guardians II and TCAR toolset
Revenue
$1.76M*
▲ 71.6% YoY
Gross margin
28.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-06
InspireMD, Inc. (NSPR) Q3 2023 Earnings Call Transcript
Revenue
$1.56M
▲ 8.7% YoY
Diluted EPS
$-0.15
Gross margin
28.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
InspireMD, Inc. (NSPR) Q2 2023 Earnings Call Transcript
Revenue
$1.65M
▲ 7.7% YoY
Diluted EPS
$-0.24
Gross margin
29.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-16
InspireMD, Inc. (NSPR) Q1 2023 Earnings Call Transcript
Revenue
$1.24M
▲ 4.7% YoY
Diluted EPS
$-0.53
Gross margin
30.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-30
InspireMD, Inc. (NSPR) Q4 2022 Earnings Call Transcript
Revenue
$1.03M*
▼ 25.7% YoY
Gross margin
19.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
InspireMD, Inc. (NSPR) Q3 2022 Earnings Call Transcript
Revenue
$1.43M
▲ 33.6% YoY
Diluted EPS
$-0.58
Gross margin
25.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
InspireMD, Inc. (NSPR) Q2 2022 Earnings Call Transcript
Revenue
$1.53M
▲ 47.5% YoY
Diluted EPS
$-0.59
Gross margin
28.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
InspireMD, Inc. (NSPR) Q1 2022 Earnings Call Transcript
Revenue
$1.18M
▲ 17.6% YoY
Gross margin
10.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-08
InspireMD, Inc. (NSPR) Q4 2021 Earnings Call Transcript
Revenue
$1.38M*
▲ 773.4% YoY
Gross margin
21.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
InspireMD, Inc. (NSPR) Q3 2021 Earnings Call Transcript
Revenue
$1.07M
▲ 9.3% YoY
Gross margin
8.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
InspireMD, Inc. (NSPR) Q2 2021 Earnings Call Transcript
Revenue
$1.04M
▲ 231.6% YoY
Gross margin
25.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
InspireMD, Inc. (NSPR) Q1 2021 Earnings Call Transcript
Revenue
$1.01M
▼ 2.7% YoY
Gross margin
10.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-10
InspireMD, Inc. (NSPR) Q4 2020 Earnings Call Transcript
Revenue
$158,000*
▼ 84.4% YoY
Gross margin
-246.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-09
InspireMD, Inc. (NSPR) Q3 2020 Earnings Call Transcript
Revenue
$980,000
▲ 4.4% YoY
Gross margin
30.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
InspireMD, Inc. (NSPR) Q2 2020 Earnings Call Transcript
Revenue
$313,000
▼ 76.9% YoY
Gross margin
-38.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
InspireMD, Inc. (NSPR) Q1 2020 Earnings Call Transcript
Revenue
$1.03M
▲ 149.2% YoY
Gross margin
28.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–25 of 25 webcasts
Key facts CIK 1433607 CUSIP 45779A846 Visit website Investor relations